SCHEMBL2387148

SCHEMBL2387148

Cc1ccccc1C(C)(O)c1cccc(O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
CASR P41180 1/20 0.41
ACHE P22303 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
ESR1 P03372 4/20 0.39
ESR2 Q92731 4/20 0.39
KIF11 P52732 4/20 0.38
HSD17B1 P14061 3/20 0.38
HSD17B2 P37059 3/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
LMNA P02545 1/20 0.37
CA5A P35218 1/20 0.37
CA9 Q16790 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11336791 0.89 CASR (0.45) GABRA1GABRB2CASRACHEESR1
SCHEMBL3848041 0.81 CASR (0.47) GABRA1GABRB2CASRACHECYP2C19
SCHEMBL19130511 0.81 CASR (0.47) GABRA1GABRB2CASRACHECYP2C19
SCHEMBL2383010 0.80 ESR1 (0.47) ACHEESR1ESR2KIF11HSD17B1
SCHEMBL874172 0.77 CASR (0.53) GABRA1GABRB2CASRACHEALDH1A1
SCHEMBL2383037 0.77 ACHE (0.59) ACHECYP1A2CYP2C19ESR1ESR2
SCHEMBL12251489 0.75 L3MBTL1 (0.44) CASRALDH1A1CYP3A4LMNA
SCHEMBL2384717 0.75 KIF11 (0.50) ACHECYP1A2CYP2C19ESR1ESR2
SCHEMBL29943758 0.73 ALDH1A1 (0.50) GABRA1GABRB2ACHEESR1ESR2
SCHEMBL548247 0.73 ALDH1A1 (0.50) GABRA1GABRB2ACHEESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 GABRA1 995/4885GABRB2 1402/4885CASR 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.